Barclays holds 17.8M Amicus shares (NASDAQ: FOLD), 5.65% stake

Rhea-AI Filing Summary

Barclays PLC reported beneficial ownership of 17,755,672 shares of Amicus Therapeutics Inc common stock, representing 5.65% of the class. The filing shows sole voting power of 17,747,658 shares and shared voting power of 8,014. The report is signed on 05/14/2026.

Insights

Institutional Ownership Analyst

Barclays discloses a significant passive stake in Amicus (5.65%).

Barclays PLC reports beneficial ownership of 17,755,672 shares, equal to 5.65% of Amicus common stock. The filing lists 17,747,658 shares with sole voting power and 8,014 with shared voting power.

Holdings are presented on a Schedule 13G; the filing classifies Barclays as an institutional investor. Subsequent filings may show changes in voting or disposition authority; the reported position size could influence passive ownership metrics disclosed in future reports.

Securities Governance Specialist

Disclosure identifies Barclays and several subsidiaries as holders and discloses control footprints.

The schedule names Barclays Bank PLC, Barclays Capital Derivative Funding, Barclays Capital Inc, and Barclays Capital Securities Ltd as related subsidiaries involved. The filing attributes voting and dispositive powers explicitly, consistent with Schedule 13G presentation requirements.

Signature block shows the report dated 05/14/2026. Any change in classification or additional schedules would be reflected in later submissions if Barclays changes intent or voting control.

Key Figures

Beneficially owned: 17,755,672 shares Percent of class: 5.65% Sole voting power: 17,747,658 shares +2 more

5 metrics

Beneficially owned 17,755,672 shares Schedule 13G reported amount

Percent of class 5.65% Percent of class as reported

Sole voting power 17,747,658 shares Number with sole power to vote

Shared voting power 8,014 shares Number with shared power to vote

Report signature date 05/14/2026 Signature date in filing

Key Terms

beneficially owned, sole voting power, Schedule 13G

3 terms

beneficially owned financial

"Amount beneficially owned: 17755672"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power regulatory

"Sole Voting Power 17,747,658.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Schedule 13G regulatory

"form_type: SCHEDULE 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AMICUS THERAPEUTICS INC

(Name of Issuer)

COMMON-STOCK

(Title of Class of Securities)

03152W109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 03152W109

1

Names of Reporting Persons

Barclays PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 17,747,658.00
6	Shared Voting Power 8,014.00
7	Sole Dispositive Power 17,747,658.00
8	Shared Dispositive Power 8,014.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

17,755,672.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.65 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AMICUS THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 47 Hulfish Street, NJ, 08542
Item 2.
(a)	Name of person filing: Barclays PLC
(b)	Address or principal business office or, if none, residence: 1 Churchill Place, London - E14 5HP
(c)	Citizenship: X0
(d)	Title of class of securities: COMMON-STOCK
(e)	CUSIP Number(s): 03152W109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 17755672
(b)	Percent of class: 5.65 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 17747658
	(ii) Shared power to vote or to direct the vote: 8014
	(iii) Sole power to dispose or to direct the disposition of: 17747658
	(iv) Shared power to dispose or to direct the disposition of: 8014
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Barclays Bank PLC, Barclays Capital Derivative Funding, Barclays Capital Inc, Barclays Capital Securities Ltd
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Barclays PLC

Signature:	Ramya Rao
Name/Title:	Director
Date:	05/14/2026

FAQ

What stake does Barclays hold in Amicus Therapeutics (FOLD)?

Barclays reports beneficial ownership of 17,755,672 shares, representing 5.65% of Amicus common stock. The filing shows sole voting power on 17,747,658 shares and shared voting power on 8,014 shares, per the Schedule 13G.

Which Barclays entities are named in the Schedule 13G for Amicus?

The Schedule 13G lists Barclays PLC and identifies related subsidiaries: Barclays Bank PLC, Barclays Capital Derivative Funding, Barclays Capital Inc, and Barclays Capital Securities Ltd as the relevant entities associated with the holding.

Does the filing indicate Barclays controls Amicus or is this passive ownership?

The filing is submitted on Schedule 13G, indicating institutional ownership reporting; it discloses voting and dispositive powers but does not assert control. Classification as passive versus active depends on intent and any subsequent filings that would change the Schedule designation.

When was the Barclays Schedule 13G for Amicus signed?

The signature block shows the form was signed by Ramya Rao on 05/14/2026. That signature date is the filing's attestation date; any later amendments would appear in subsequent SEC submissions if holdings or classifications change.